Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Study:

A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression

Rationale:

n/a

Purpose:

The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Bipolar I Depression Drug: RG2417
Drug: Placebo
Phase 2

Verified by Repligen Corporation January, 2011

Sponsored by: Repligen Corporation
Information provided by: Repligen Corporation
ClinicalTrials.gov identifier: NCT00812058

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Gary Sachs, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site